Last reviewed · How we verify

Temsirolimus, Rituximab, Bendamustin

Georg Hess, MD · Phase 1 active Small molecule

Temsirolimus, Rituximab, Bendamustin is a Small molecule drug developed by Georg Hess, MD. It is currently in Phase 1 development. Also known as: Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda.

At a glance

Generic nameTemsirolimus, Rituximab, Bendamustin
Also known asMabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda
SponsorGeorg Hess, MD
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Temsirolimus, Rituximab, Bendamustin

What is Temsirolimus, Rituximab, Bendamustin?

Temsirolimus, Rituximab, Bendamustin is a Small molecule drug developed by Georg Hess, MD.

Who makes Temsirolimus, Rituximab, Bendamustin?

Temsirolimus, Rituximab, Bendamustin is developed by Georg Hess, MD (see full Georg Hess, MD pipeline at /company/georg-hess-md).

Is Temsirolimus, Rituximab, Bendamustin also known as anything else?

Temsirolimus, Rituximab, Bendamustin is also known as Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda.

What development phase is Temsirolimus, Rituximab, Bendamustin in?

Temsirolimus, Rituximab, Bendamustin is in Phase 1.

Related